focus -WSS

focus

author：fashion 2025-10-01 02:27:36 - browse：6

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Crowdfunding for unproven stem cell procedures spreads misinformation

hotspot

explore

WSS

Profiling embryos to choose those with higher IQs is almost a reality

Hubble vs. James Webb telescope images: See the difference

Profiling embryos to choose those with higher IQs is almost a reality

Drug cartel violence flares in western Mexico after vigilante leader's killing

The biotech scorecard for Q3: 15 stock

Hospital chaplains balance Covid safety with patients’ spiritual needs

Wikipedia

focus

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Security flaws in third

ChatGPT in medicine: STAT answers readers' burning questions

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Novavax promises a turnaround & Lilly roils the obesity market

Security flaws in third

The high cost of giving birth even with insurance

Dexcom's push to bring CGM to type 2 diabetes patients

The high cost of giving birth even with insurance

The biotech scorecard for Q3: 15 stock

entertainment

Lupron, used to halt puberty in children, may cause lasting health problems

Stories you might have missed in 2023: health, science, medicine

Use doctors trained outside the U.S. to ease the physician shortage

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Profiling embryos to choose those with higher IQs is almost a reality

Profiling embryos to choose those with higher IQs is almost a reality

hotspot

explore

entertainment

hotspot